Haemonetics shares rose about 7% in premarket trading after the company disclosed a supply agreement with Australian biopharma CSL Limited. Under the non-exclusive deal, CSL Plasma will use Haemonetics' NexSys PCS devices with Persona PLUS technology and purchase related disposables in the U.S. CSL, which operates one of the world's largest plasma collection networks, is also expected to roll out the devices and disposables across some of its U.S. plasma collection centers. Haemonetics did not update its fiscal 2027 outlook, citing uncertain implementation timing, and plans to discuss the financial impact during its second-quarter fiscal 2027 earnings call in November.
Haemonetics CorporationSupply agreement with CSL for NexSys PCS devices and disposables boosts product demand.
CSL secures supply of Haemonetics' plasma collection devices, enhancing its collection operations.
